A RANDOMIZED PHASE II TRIAL OF EPOCH (AIDS)

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。在国家癌症研究所进行的试点试验中，75%以上新诊断的艾滋病相关淋巴瘤患者输注EPOCH（依托泊苷、强的松、Oncovin、环磷酰胺、羟霉素（多柔比星））化疗与持久完全缓解相关。本试验的目的是确定在EPOCH方案中加入单克隆抗体利妥昔单抗是否会提高新诊断的艾滋病相关b细胞淋巴瘤患者的完全缓解率及其持久性。在这项由NCI-AIDS恶性肿瘤协会赞助的多中心试验中，70名患者将随机接受利妥昔单抗，或与ePOCH同时给予，或作为维持治疗。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. In pilot trials conducted at the National Cancer Institute, infusional chemotherapy with EPOCH (etoposide, prednisone, Oncovin, cyclophosphamide, hydroxydaunomycin (doroxubicin) is associated with durable complete remission in over 75% of patients with newly diagnosed AIDS-related lymphomas. The purpose of this trial is to determine if the addition of the monoclonal antibody rituximab to the EPOCH regimen will improve the complete remission rate and its durability in the treatment of newly diagnosed patients with AIDS-related B-cell lymphomas. In this multi-center trial sponsored by the NCI-AIDS Malignancy consortium, 70 patients will be randomized to receive either rituximab either given concurrently with ePOCH or as maintenance therapy.